Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives by Byeong-Hyeon Kim, Sujin Kim, Yunkwon Nam, Yong Ho Park, Seong Min Shin, Minho Moon

“…Abstract Alzheimer’s disease (AD) is the most common type of dementia. Monoclonal antibodies (MABs) serve as a promising therapeutic approach for AD by selectively targeting key pathogenic factors, such as amyloid-β (Aβ) peptide, tau protein, and neuroinflammation. …”
Get full text

Application of Monoclonal Antibodies against Bioactive Natural Products: Eastern Blotting and Preparation of Knockout Extract by Hiroyuki Tanaka, Osamu Morinaga, Takuhiro Uto, Shunsuke Fuji, Frederick Asare Aboagye, Nguyen Huu Tung, Xiao Wei Li, Waraporn Putalun, Yukihiro Shoyama

Get full text

Performance analysis of Leica Biosystems p16 monoclonal antibody in oropharyngeal squamous cell carcinoma by Selvam Thavaraj, Max Robinson, Shubham Dayal, Claire Bowen

“…Conclusion LBS p16 monoclonal antibody demonstrated high concordance with CINtec p16 IHC assay across all the endpoints, suggesting a potential use of LBS RTU p16 clone in detecting p16 protein in oropharyngeal cancer cases.…”
Get full text

Charge heterogeneity of therapeutic monoclonal antibodies by different cIEF systems: views on the current situation by Alessandro Ascione, Marcello Belfiore, Jaana Vesterinen, Mihaela Buda, Wolf Holtkamp, Francesca Luciani

“…Here, we discuss the results of an analysis of a panel of antibody products by conventional and whole-column imaging cIEF systems performed as part of European Pharmacopoeia activities related to development of “horizontal standards” for the quality control of monoclonal antibodies (mAbs). The study aimed at designing and verifying an independent and transversal cIEF procedure for the reliable analysis of mAbs charge variants. …”
Get full text

New approach to generating of human monoclonal antibodies specific to the proteolytic domain of botulinum neurotoxin A by Marina Vladimirovna Silkina, Alena Sergeevna Kartseva, Alena Konstantinovna Riabko, Mariia Aleksandrovna Makarova, Metkhun Madibronovich Rogozin, Yana Olegovna Romanenko, Igor Georgievich Shemyakin, Ivan Alekseevich Dyatlov, Victoria Valerievna Firstova

Subjects: Get full text

Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist by So Yeong Jeong, Chong Hyun Suh, Jae-Sung Lim, Yangsean Choi, Ho Sung Kim, Sang Joon Kim, Jae-Hong Lee

Get full text

Biodistribution of 89Zr-Radiolabeled Nanoassemblies for Monoclonal Antibody Delivery Revealed through In Vivo PET Imaging by Ana M. López-Estévez, Amaia Carrascal-Miniño, Dolores Torres, María José Alonso, Rafael T. M. de Rosales, Juan Pellico

Get full text

Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review by Hannah W. Haddad, Garett W. Malone, Nicholas J. Comardelle, Arielle E. Degueure, Salomon Poliwoda, Rachel J. Kaye, Kevin S. Murnane, Adam M Kaye, Alan D. Kaye

“…The present investigation describes the epidemiology, pathophysiology, risk factors, presentation, and current treatment of AD followed by the role of the novel monoclonal antibody, Adulhelm, in the treatment of AD. Currently, Adulhelm is the only Food and Drug Administration (FDA) approved drug that acts to slow the progression of this disease. …”
Get full text

Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome by Alessandra Petrillo, Noa Biran, Sean Sadikot

“…We discuss a case of a patient with multiple myeloma who was hospitalized with drug-induced ARDS who had a rapid response to an anti-interleukin-6 monoclonal antibody.…”
Get full text

Practical solutions for overcoming artificial disulfide scrambling in the non-reduced peptide mapping characterization of monoclonal antibodies by Andrew Kleinberg, Yuan Mao, Ning Li

“…Non-reduced peptide mapping provides essential data for characterizing therapeutic monoclonal antibodies by isolating disulfide connections between specific cysteines. …”
Get full text

Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities by Nai Lee, Su‐jin Rhee, Seong Min Koo, So Won Kim, Gyo Eun Lee, Yoon A Yie, Yun Kim

Subjects: Get full text

New specific migraine prevention: monoclonal antibodies against calcitonin gene-related peptide and its receptor by K. Ryliškienė, D. Jatužis, A. Vaitkus

Subjects: Get full text

Development of monoclonal antibodies against P. gingivalis Mfa1 and their protective capacity in an experimental periodontitis model by Mingya Cao, Siyu Wang, Shengke Zhou, Min Yan, Yu Zou, Yuan Cui, Xinyu Lou, Yichang Gao, Ying Chen, Zijing Han, Yi Qian, Jingying Chen, Xia Li

Subjects: Get full text

Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review by Hannah W Haddad, Garett W. Malone, Nicholas J. Comardelle, Arielle E. Degueure, Adam M. Kaye, Alan D. Kaye

“…This review discusses the epidemiology, pathophysiology, risk factors, presentation, and current treatment of AD followed by the role of the novel monoclonal antibody, aducanumab, in treatment of AD. Currently aducanumab is the only Food and Drug Administration (FDA) approved drug that acts to slow progression of this disease. …”
Get full text

Pair combinations of human monoclonal antibodies fully protected mice against bunyavirus SFTSV lethal challenge. by Bang Li, Xiang-Rong Qin, Jia-Chen Qu, Guan-du Wu, Wen-Kang Zhang, Ze-Zheng Jiang, Pan-Pan Liu, Ze-Min Li, Tian-Mei Yu, Chuan-Min Zhou, Yong-Jun Jiao, Xue-Jie Yu

“…Currently, there is no vaccine or effective therapy for SFTS. Neutralizing monoclonal antibody therapy, which provides immediate passive immunity and may limit disease progression, has emerged as a reliable approach for developing therapeutic drugs for SFTS. …”
Get full text

Generation of Recombinant Porcine Parvovirus Virus-Like Particles in Saccharomyces cerevisiae and Development of Virus-Specific Monoclonal Antibodies by Paulius Lukas Tamošiūnas, Rasa Petraitytė-Burneikienė, Rita Lasickienė, Artiomas Akatov, Gabrielis Kundrotas, Vilimas Sereika, Raimundas Lelešius, Aurelija Žvirblienė, Kęstutis Sasnauskas

“…Electron microscopy analysis of purified PPV VP2 protein revealed the self-assembly of virus-like particles (VLPs). Nine monoclonal antibodies (MAbs) against the recombinant PPV VP2 protein were generated. …”
Get full text

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis by Arun Hegde, Vivek Vasdev, Krishnan Shanmuganandan, Kavita Singh, Sivasami Kartik, Abhishek Kumar

“…Background: Rituximab (RTX), an anti-CD 20 monoclonal antibody is one of the first line biological disease-modifying anti-rheumatoid drug indicated for the treatment of rheumatoid arthritis (RA) in patient's refractory to conventional Synthetic DMARDs (csDMARDs). …”
Get full text

Non-invasive imaging with ICOS-targeting monoclonal antibody for preclinical diagnosis of rheumatoid arthritis in a humanized mouse model by Shao Duan, Chao Li, Feng Yan, Yifei Xia, Shuaiming Shao, Weiyu Chen, Zunyu Xiao, Gongping Xu

“…Anti-human ICOS monoclonal antibody (mAb) was conjugated to Cy7 via NHS ester amine reaction. …”
Get full text

Anti-Tn Monoclonal Antibody Ameliorates Hyperoxia-Induced Kidney Injury by Suppressing Oxidative Stress and Inflammation in Neonatal Mice by Julie Chi Chow, Hsiu-Chu Chou, Jaulang Hwang, Chung-Ming Chen

“…The mice were divided into four study groups: RA + PBS, RA + anti-Tn monoclonal antibody, O2 + PBS, and O2 + anti-Tn monoclonal antibody. …”
Get full text

Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations by Melanie Maier, Linus Weiß, Nikolas Zeh, Valerie Schmieder-Todtenhaupt, Alireza Dehghani, Marius Nicolaus Felix, Daniel Heinzelmann, Benjamin Lindner, Moritz Schmidt, Joey Studts, Patrick Schulz, Bernd Reisinger, Kerstin Otte, Matthias Franzreb, Daniel Lakatos, Simon Fischer

“…Monoclonal antibodies (mAb) and other biological drugs are affected by enzymatic polysorbate (PS) degradation that reduces product stability and jeopardizes the supply of innovative medicines. …”
Get full text